- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04099433
Application of Oral Bacteriotherapy to Promote Anal HPV Clearance in HIV Positive Individuals (HPVinHIV)
HPVinHIV: Study of Anal HPV Infection in the Setting of HIV Infected Individuals
Published studies suggest that oral probiotic intake can promote the clearance of HPV genital infection and HPV related genital dysplasia in HIV negative women. In the present randomized, double blind, placebo controlled study, investigators will evaluate the ability of oral bacterio-therapy to enhance the clearance of anal HPV infection and anal HPV related dysplasia in HIV infected subjects.
Participants will be evaluated for anal HPV infection and anal dysplasia before and after a 6 months course of daily investigational product intake (Viviomixx® or placebo). HPV infection rate and presence of dysplasia at baseline and at the end of the study will be compared.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Squamous Cell Carcinoma (SCC) of the anus and the anal canal represents a major concern for the HIV infected population, with incidence rates in the different sub populations (women, men, MSM) that are grater than those observed for other common neoplasms in the same HIV negative sub-populations. Nowadays, screening for anal precancerous dysplasia has been included in most national and international HIV management guidelines; in particular, italian guidelines suggest to screen for the presence of HPV related dysplasia:
- HIV+ MSM
- All individuals with previous or current evidence of ant-genital condyloma
- Women with cytology abnormalities on cervical Pap-smear Since no direct anti-HPV drug is currently available and control or clearance of the infection is possible only trough the effect of immune response, interest is addressed to find strategies to promote spontaneous clearance of infection.
In published studies, oral bacterio-therapy demonstrated the ability to promote HPV clearance and HPV related dysplasia regression in HIV negative women.
In the present randomized, double blind, placebo controlled trial, 40 HIV infected individuals with HPV related anal dysplasia will be enrolled.
At baseline participants will undergo:
- anal HPV research and identification
- anal cytology
- anal brushing for evaluation of local inflammatory milieu and microbiota
Subjects with identified HPV anal infection and anal dysplasia will undergo High Resolution Anoscopy (HRA).
During HRA, extra biopsies of identified abnormal areas and biopsies of normal mucosa will be obtained. Extra biopsies will be used to investigate the distribution of intra-epithelial immune cells populations.
Participants will then undergo 6 months of oral supplementation with probiotics (Vivomixx®) or placebo.
At the end of the supplementation period (Vivomixx or placebo), participants will undergo:
- anal HPV research and identification
- anal cytology
- anal brushing for evaluation of local inflammatory milieu and microbiota
- HRA
During HRA, extra biopsies of identified abnormal areas and biopsies of normal mucosa will be obtained. Extra biopsies will be used to investigate the distribution of intra-epithelial immune cells populations.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gabriella d'Ettorre, Professor, MD
- Phone Number: 0649970801
- Email: gabriella.dettorre@uniroma1.it
Study Contact Backup
- Name: Eugenio Nelson Cavallari, MD
- Email: eugenionelson.cavallari@uniroma1.it
Study Locations
-
-
RM
-
Rome, RM, Italy, 00100
- Recruiting
- Department of Pubblic Health and Infectious Diseases, "Sapienza" University of Rome
-
Contact:
- Eugenio Nelson Cavallari, MD
- Email: eugenionelson.cavallari@uniroma1.it
-
Contact:
- Gabriella d'Ettorre, Professor
- Email: gabriella.dettorre@uniroma1.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV infected individuals >18 years old
- stable and effective antiretroviral therapy since at least 12 months
- HPV associated anal dysplasia
- patient willing to provide written informed consent
Exclusion Criteria:
- impossibility to intake the investigational product
- any contraindication to blood sampling
- inflammatory bowel disease
- use of antibiotics during the 3 months prior to the enrollment in the study
- pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Oral Bacteriotherapy Arm
Individuals in this study arm will undergo 6 months of daily intake of an oral probiotic formulation (Vivomixx: 4 sachets/day, each sachet containing 450 billion live bacteria).
Probiotic sachets are indistinguishable from placebo
|
Individuals in the interventional arm will undergo daily oral intake of probiotic supplement
|
PLACEBO_COMPARATOR: Placebo Arm
Individuals in this study arm will undergo 6 months of daily intake of placebo (4 sachets/day).
Placebo sachets are indistinguishable from probiotic
|
Individuals in the placebo arm will undergo daily oral intake of placebo supplement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the number of HPV positive anal swabs
Time Frame: Anal swabs for HPV detection and genotyping will be performed at baseline and after the 6 months duration of the intervention
|
Clearance of anal HPV infection will be defined as:
|
Anal swabs for HPV detection and genotyping will be performed at baseline and after the 6 months duration of the intervention
|
Change from baseline in the number of dysplastic lesions
Time Frame: Areas of the anal canal that were biopsied at baseline and whom histology showed the presence of dysplasia will undergo a second biopsy after the 6 months duration of the intervention
|
Clearance of anal dysplasia will be defined as: - normal histology in biopsies repeated at the end of the study on areas that showed the presence of histologically defined dysplasia at baseline. |
Areas of the anal canal that were biopsied at baseline and whom histology showed the presence of dysplasia will undergo a second biopsy after the 6 months duration of the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of adverse events
Time Frame: This measure will be assessed after the 6 months duration of the intervention
|
The rate of adverse events occurred during the study period will be evaluated and compared between both groups
|
This measure will be assessed after the 6 months duration of the intervention
|
Comparison between intra-epithelial NK lymphocytes subpopulation in normal mucosa and dysplastic mucosa
Time Frame: Biopsies and intra-epithelial lymphocytes extraction will be performed at baseline and after the 6 months duration of the intervention
|
Biopsies from dysplastic lesions and from normal mucosa will be taken at baseline.
Biopsies will also be taken at the end of the study from previously biopsied areas, from normal mucosa and eventually from dysplastic areas that were not present at baseline.
Intra-epithelial lymphocytes will be extracted from the biopsy tissue and stained to differentiate and quantify CD56+NK lymphocytes by flowcytometry.
Changes from baseline will be expressed as relative difference.
|
Biopsies and intra-epithelial lymphocytes extraction will be performed at baseline and after the 6 months duration of the intervention
|
Comparison between intra-epithelial CD4+ T lymphocytes subpopulation in normal mucosa and dysplastic mucosa
Time Frame: Biopsies and intra-epithelial lymphocytes extraction will be performed at baseline and after the 6 months duration of the intervention
|
Biopsies from dysplastic lesions and from normal mucosa will be taken at baseline.
Biopsies will also be taken at the end of the study from previously biopsied areas, from normal mucosa and eventually from dysplastic areas that were not present at baseline.
Intra-epithelial lymphocytes will be extracted from the biopsy tissue and stained to differentiate and quantify CD4+ T lymphocytes by flowcytometry.
Changes from baseline will be expressed as relative difference.
|
Biopsies and intra-epithelial lymphocytes extraction will be performed at baseline and after the 6 months duration of the intervention
|
Comparison between intra-epithelial CD8+ T lymphocytes subpopulation in normal mucosa and dysplastic mucosa
Time Frame: Biopsies and intra-epithelial lymphocytes extraction will be performed at baseline and after the 6 months duration of the intervention
|
Biopsies from dysplastic lesions and from normal mucosa will be taken at baseline.
Biopsies will also be taken at the end of the study from previously biopsied areas, from normal mucosa and eventually from dysplastic areas that were not present at baseline.
Intra-epithelial lymphocytes will be extracted from the biopsy tissue and stained to differentiate and quantify CD8+ T lymphocytes by flowcytometry.
Changes from baseline will be expressed as relative difference.
|
Biopsies and intra-epithelial lymphocytes extraction will be performed at baseline and after the 6 months duration of the intervention
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 4590
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on Vivomixx
-
Singapore General HospitalUnknownSystemic SclerosisSingapore
-
Centre Hospitalier Universitaire de NiceRecruitingNeurocognitive Disorders | HIVFrance
-
Lund UniversityCompleted
-
University of Modena and Reggio EmiliaUnknownExercise Addiction | Dietary Modification | High-Risk Pregnancy | Gestational Diabetes Mellitus in Pregnancy, Diet- ControlledItaly
-
Fundació Institut de Recerca de l'Hospital de la...WithdrawnSpontaneous Bacterial PeritonitisSpain
-
IRCCS Fondazione Stella MarisMinistry of Health, Italy; Istituto di Fisiologia Clinica CNRCompletedAutism Spectrum DisorderItaly
-
Fundació Institut de Recerca de l'Hospital de la...Spanish Clinical Research Network - SCReNWithdrawn
-
Chinese University of Hong KongNot yet recruitingPregnancy Related | Microtia | Neonatal Jaundice
-
Hvidovre University HospitalUniversity of Copenhagen; Statens Serum InstitutCompletedObesity | Pregnancy | Gestational Diabetes MellitusDenmark
-
International Centre for Diarrhoeal Disease Research...Bill and Melinda Gates FoundationRecruitingEnvironmental Enteric Dysfunction | Gut Microbiota DysbiosisBangladesh